<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312471872</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312471872</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Serum tumour necrosis factor-alpha is associated with poor health-related quality of life and depressive symptoms in patients with systemic lupus erythematosus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Mak</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312471872">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203312471872"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Tang</surname><given-names>CS</given-names></name>
<xref ref-type="aff" rid="aff2-0961203312471872">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ho</surname><given-names>RC</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312471872">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203312471872"><label>1</label>Division of Rheumatology, Department of Medicine, University Medicine Cluster, Yong Loo Lin School of Medicine, National University of Singapore, Singapore</aff>
<aff id="aff2-0961203312471872"><label>2</label>Department of Psychology, Faculty of Arts and Social Sciences, National University of Singapore, Singapore</aff>
<aff id="aff3-0961203312471872"><label>3</label>Department of Psychological Medicine, University Medicine Cluster, Yong Loo Lin School of Medicine, National University of Singapore, Singapore</aff>
<author-notes>
<corresp id="corresp1-0961203312471872">Anselm Mak, MMedSc, MBBS, MD, FRCP(Edin), Division of Rheumatology, University Medicine Cluster, 1E Kent Ridge Road, Level 10, NUHS Tower Block, Singapore 119228. Email: <email>mdcam@nus.edu.sg</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>3</issue>
<fpage>254</fpage>
<lpage>261</lpage>
<history>
<date date-type="received"><day>22</day><month>7</month><year>2012</year></date>
<date date-type="accepted"><day>27</day><month>11</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012. Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec>
<title>Objectives</title>
<p>While patients with systemic lupus erythematosus (SLE) have poorer health-related quality of life (HRQoL) and are more depressed than healthy people, the impact of proinflammatory cytokines, particularly tumour necrosis factor-alpha (TNFα), on these unfavourable psychosocial parameters is unclear. We aim to explore potential relationships between lupus-related proinflammatory cytokines, HRQoL and depressive symptoms in patients with SLE.</p>
</sec>
<sec>
<title>Methods</title>
<p>Patients with SLE and age-matched healthy subjects were assessed for HRQoL and depressive and anxiety symptoms by the Short Form Health Survey-36 (SF-36) and Hospital Anxiety and Depression Scale (HADS) respectively. Using multiplex immunoassay, a panel of serum proinflammatory cytokines including TNFα, interleukin (IL)-1β, IL-6, IL-17, IL-23 and IL-33 were determined and compared between both groups. Independent associations between SF-36, serum proinflammatory cytokine levels and HADS scores were studied by regression models.</p>
</sec>
<sec>
<title>Results</title>
<p>In total, 54 patients and 54 healthy controls were studied. Lupus patients had significantly poorer HRQoL (<italic>p</italic> &lt; 0.001) and were significantly more depressed (<italic>p</italic> = 0.006) and anxious (<italic>p</italic> = 0.022) than their healthy counterparts. Amongst the proinflammatory cytokines studied, serum TNFα was significantly higher in lupus patients (<italic>p</italic> &lt; 0.001). After multivariate adjustment, higher serum TNFα (β = −0.224, <italic>p</italic> = 0.047) remained significantly associated with lower SF-36, along with smoking (β = −0.253, <italic>p</italic> = 0.014) and more severe depressive symptoms (β = −0.433, <italic>p</italic> = 0.002). In healthy subjects, serum TNFα was associated with depressive symptoms but not with SF-36.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Higher serum TNFα level is independently associated with poorer HRQoL and more severe depressive symptoms in SLE patients. These associations suggest a potential impact of inflammatory response on depressive symptoms and the quality of life in patients with SLE.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Proinflammatory cytokines</kwd>
<kwd>tumour necrosis factor alpha</kwd>
<kwd>systemic lupus erythematosus</kwd>
<kwd>depression</kwd>
<kwd>health-related quality of life</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312471872" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune mediated inflammatory disorder which not only leads to acute immune-mediated tissue injury and chronic damage accrual but also exerts an unfavourable impact on health-related quality of life (HRQoL) and psychosocial well-being.<sup><xref ref-type="bibr" rid="bibr1-0961203312471872">1</xref>,<xref ref-type="bibr" rid="bibr2-0961203312471872">2</xref></sup> The magnitude of HRQoL reduction in patients with SLE is as substantial as that observed in those suffering from other chronic illnesses such as acquired immunodeficiency syndrome, post-myocardial infarction and congestive heart failure, which are perceived as being more severe than SLE.<sup><xref ref-type="bibr" rid="bibr3-0961203312471872">3</xref>–</sup><sup><xref ref-type="bibr" rid="bibr5-0961203312471872">5</xref></sup> In addition, patients with SLE are significantly more depressed and anxious than those with other commonly encountered autoimmune inflammatory conditions such as rheumatoid arthritis (RA) and gout.<sup><xref ref-type="bibr" rid="bibr6-0961203312471872">6</xref></sup> Besides the use of long-term medications, disease damage and loss of productivity which hamper the quality of life of lupus patients,<sup><xref ref-type="bibr" rid="bibr2-0961203312471872">2</xref>,<xref ref-type="bibr" rid="bibr7-0961203312471872">7</xref>,<xref ref-type="bibr" rid="bibr8-0961203312471872">8</xref></sup> it is reasonable to postulate that, being an immune-complex mediated condition, disease-related factors such as inflammation can impart negative influence on the mental well-being and HRQoL of patients with SLE. There are several lines of circumferential evidence to support this. For instance, an increase in proinflammatory cytokines including tumour necrosis factor-alpha (TNFα), interleukin (IL)-1 and IL-6 secondary to viral infection and chronic stress can lead to sickness behaviour characterized by fatigue, sleep disturbance, irritability, loss of appetite, depressive mood and even social withdrawal.<sup><xref ref-type="bibr" rid="bibr9-0961203312471872">9</xref></sup> Interferon-alpha (IFNα), which can trigger the release of IL-6 and TNFα in lymphocytes and is elevated in patients with active lupus, has been well described for its ability to trigger depressive symptoms in up to 40% of patients who use the cytokine for treating viral hepatitis and malignant melanoma.<sup><xref ref-type="bibr" rid="bibr10-0961203312471872">10</xref>,<xref ref-type="bibr" rid="bibr11-0961203312471872">11</xref></sup> Therefore, it appears that proinflammatory cytokines are capable of adversely affecting the HRQoL and psychosocial well-being of patients with SLE. Here, we aim to investigate whether the serum levels of proinflammatory cytokines, in particular TNFα, are (i) elevated in patients with SLE and (ii), independently associated with poorer HRQoL and more severe depressive symptoms.</p>
</sec>
<sec id="sec2-0961203312471872" sec-type="methods"><title>Methods</title>
<sec id="sec3-0961203312471872"><title>Subject recruitment and assessment of psychosocial parameters and HRQoL</title>
<p>Patients with SLE who fulfilled the American College of Rheumatology (ACR) classification for SLE were recruited from the Lupus Clinic, National University Hospital (NUH), Singapore.<sup><xref ref-type="bibr" rid="bibr12-0961203312471872">12</xref></sup> Patients with current or past history of dysthyroidism, diabetes, hypertension, cerebrovascular and cardiovascular diseases, cardiac failure and psychiatric conditions were excluded in order to minimize their potential confounding effects on HRQoL and other psychosocial variables. Healthy subjects matched for age were recruited for comparison. These normal healthy controls were mainly clinic nurses of the medical outpatient clinic of NUH and their relatives who did not have any chronic medical and/or psychiatric illness or a history of long-term medication use prior to or at the time of recruitment for this study. Both patients and healthy subjects who had acute illness at recruitment were also excluded. For all the participants, the HRQoL and the severity of anxiety and depressive symptoms were assessed by the Short Form Health Survey-36 (SF-36) and Hospital Anxiety and Depression Scale (HADS) respectively.<sup><xref ref-type="bibr" rid="bibr13-0961203312471872">13</xref>,<xref ref-type="bibr" rid="bibr14-0961203312471872">14</xref></sup> Amongst patients with SLE, disease activity and damage accrual were assessed by the SLE disease activity index (SLEDAI) and Systemic Lupus International collaborating clinics/American College of Rheumatology damage index for SLE (SLICC/ACR DI) respectively.<sup><xref ref-type="bibr" rid="bibr15-0961203312471872">15</xref>,<xref ref-type="bibr" rid="bibr16-0961203312471872">16</xref></sup> A trained postgraduate student obtained all the demographic, clinical and psychosocial data through clinical interview and medical record review. Written informed consent was obtained from all the participants before recruitment.</p>
</sec>
<sec id="sec4-0961203312471872"><title>Determination of serum proinflammatory cytokine levels</title>
<p>After clinical interview, 5–8 ml of peripheral blood was obtained by venepuncture through the antecubital vein from all the subjects. The blood was allowed to clot at room temperature (RT) for 30 min and the serum was centrifuged at 1300 <italic>g</italic> for 10 min at 4°C. Serum samples were aliquoted into Eppendorf tubes and stored at −80°C for subsequent analysis.</p>
<p>To simultaneously analyse several cytokines from small volumes of serum samples, the combination of a panel of serum proinflammatory cytokines comprising TNFα, IL-1ß, IL-6, IL-17, IL-23 and IL-33<sup><xref ref-type="bibr" rid="bibr17-0961203312471872">17</xref>–</sup><sup><xref ref-type="bibr" rid="bibr19-0961203312471872">19</xref></sup> was determined by the multiplex immunoassay (Miliplex® Human Cytokine/Chemokine panel, Millipore®) based on the Luminex® xMAP® platform. In brief, 200 µl of wash buffer was added to each well of the 96-well microplates. After shaking for 10 min at RT and washing, 25 µl of standard and control were added to the appropriate wells, followed by addition of 25 µl of assay buffer and matrix to the background, samples and control wells. Thawed serum samples of 25 µl at RT were pipetted into each sample well, followed by adding 25 µl of fluorescent beads (microspheres) which were bound with anti-human TNFα, IL‐1β, IL-6, IL-17, IL-23 and IL-33 antibodies. After incubation at 4°C overnight for 18 h, the microplates were washed twice before adding 25 µl of detection antibodies followed by incubation for 1 h at RT. Then, 25 µl of streptavidin-phycoerythrin was added to each well with incubation at RT for 30 min. The microplates were then washed twice with 200 µl wash buffer before adding 150 µl sheath fluid per well. Finally, the microplates were read on Luminex 100<sup>TM</sup> IS. Data in the form of Median Fluorescent Intensity (MFI) were analysed using a five-parameter logistic curve-fitting model for calculating the cytokine concentrations in the samples. The intra- and inter-assay coefficients of variation (CV) of the IL-1ß, IL-6, IL-17, TNFα, IL-23 and IL-33 assays were 6.1, 8.1, 4.5, 10.5, 14.2 and 10.3, and 7.0, 11.6, 9.9, 15.9, 14.5 and 16.7, respectively. All serum samples were thawed once only for the assays and all the assays were performed in duplicate.</p>
</sec>
<sec id="sec5-0961203312471872"><title>Sample size calculation</title>
<p>We first sought to ensure significant difference between lupus patients and healthy controls in HRQoL with the aim of increasing the probability of demonstrating a difference in serum TNFα level between the two groups. Based on our preliminary study which addressed the differences in HRQoL and mood symptoms between lupus patients and healthy subjects,<sup><xref ref-type="bibr" rid="bibr6-0961203312471872">6</xref></sup> we calculated the sample size according to differences of 8.74 and 11.19 units in physical component score (PCS) and mental component score (MCS), respectively, of SF-12 between the patients and healthy controls. A sample size of ≥14 in each group was required to achieve a power of 90% and alpha of 5% to detect a statistically significant difference in HRQoL. As for serum proinflammatory cytokines, based on previous published data from other centres, a sample size of 52 was required to show statistically significant difference in serum TNFα between patients with SLE and healthy controls.<sup><xref ref-type="bibr" rid="bibr20-0961203312471872">20</xref>,<xref ref-type="bibr" rid="bibr21-0961203312471872">21</xref></sup> Since this is an exploratory study to address a correlation between serum proinflammatory cytokine levels and HRQoL in patients with SLE, we aimed to recruit least 52 patients and 52 age-matched healthy subjects between April 2011 and March 2012, during which this study had been approved by the research ethics committee of our institution.</p>
</sec>
<sec id="sec6-0961203312471872"><title>Statistical analysis</title>
<p>Values were expressed as mean ± standard deviation (SD) unless otherwise specified. Normality of the data was evaluated by the Kolmogorov–Smirnov test. Student’s <italic>t</italic>-test or Mann–Whitney <italic>U</italic> test was used to examine the differences between the two groups for continuous variables where appropriate while the χ<sup>2</sup> test was used for comparing categorical variables. Univariate linear regression analysis was used to determine the relationships of demographic, clinical and psychosocial as well as serological variables and SF-36. Continuous variables were log-transformed (Ln<sub>10</sub>(<italic>x</italic>) or Ln<sub>10</sub>(<italic>y</italic> + 1) if <italic>y</italic> contained zero in a variable) before they were fitted into the linear regression model if they were not normally distributed or if equal variance could not be assumed. Multiple regression models were constructed to identify variables which were independently associated with SF-36. Due to the limited sample size and to ensure the stability of the regression models, only variables with <italic>p</italic> &lt; 0.2 in the univariate analysis were entered into the multiple regression equation using forced entry. To ascertain the validity of the regression model, only potential independent variables with tolerance &gt;0.4 and variance inflation factor (VIF) &lt;10, which indicate minimal collinearity, would be accepted in the final regression model.<sup><xref ref-type="bibr" rid="bibr22-0961203312471872">22</xref></sup> To demonstrate the validity of the final regression model, P-P plot of standardized residuals and scatter plot of regression standardized predicted values versus regression standardized residuals would be shown (see Supplementary Figures 1 and 2 online). All statistical analyses were performed by the PASW Statistics (SPSS version 18.0, Chicago, IL, USA). A two-tailed <italic>p</italic>-value of &lt;0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="sec7-0961203312471872" sec-type="results"><title>Results</title>
<p>Fifty-four SLE patients and 54 age-matched healthy controls were studied; 82% and 89% were female in the healthy control and SLE groups respectively. There were no significant differences between the two groups in gender, marital and smoking status, ethnicity and duration of education. In the SLE group, the mean (±SD) SLEDAI and the daily prednisolone dose were 3.85 ± 3.8 (range 0–16) and 10.47 ± 12.1 mg (range 0–40) respectively. The SLICC/ACR DI was 0.39 ± 0.8 unit. For the psychosocial parameters, both the mean (±SD) anxiety and depression scores in the SLE group were significantly higher than those of the healthy controls (for anxiety: 5.65 ± 4.1 <italic>vs</italic>. 3.74 ± 2.9 units, <italic>p</italic> = 0.022; for depression: 3.87 ± 3.0 <italic>vs</italic>. 2.33 ± 2.3 units, <italic>p</italic> = 0.006). Using the cut-off score of 8 of the HADS to define anxiety and depression,<sup><xref ref-type="bibr" rid="bibr6-0961203312471872">6</xref></sup> significantly more lupus patients had anxiety (35% <italic>vs</italic>. 11%, <italic>p</italic> = 0.005) and a trend of higher proportion of depression was found in the SLE group (15% <italic>vs</italic>. 7%, <italic>p</italic> = 0.359). As for HRQoL, the mean (±SD) scores of SF-36 and its physical health (PH) and mental health (MH) components in the SLE group were significantly lower than those of the healthy subjects (SF-36: 67.87 ± 19.8 <italic>vs</italic>. 84.53 ± 8.7, <italic>p</italic> &lt; 0.001; PH: 66.98 ± 19.1 <italic>vs</italic>. 82.37 ± 9.8, <italic>p</italic> &lt; 0.001; MH: 64.46 ± 20.0 <italic>vs</italic>. 80.15 ± 11.2, <italic>p</italic> &lt; 0.001). <xref ref-type="table" rid="table1-0961203312471872">Table 1</xref> summarizes the comparison of demographic and clinical data between lupus patients and healthy controls. <xref ref-type="table" rid="table2-0961203312471872">Table 2</xref> depicts the anxiety and depressive symptoms and HRQoL between patients with SLE and healthy subjects.
<table-wrap id="table1-0961203312471872" position="float"><label>Table 1</label><caption><p>Demographic and clinical data of patients with SLE and healthy controls</p></caption>
<graphic alternate-form-of="table1-0961203312471872" xlink:href="10.1177_0961203312471872-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>SLE (N = 54)<hr/></th>
<th>Healthy controls (N = 54)</th>
<th>p-value</th>
</tr>
<tr><th/>
<th colspan="3">Mean ± SD; number (%)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Age, years</td>
<td>40.59 ± 14.8</td>
<td>40.02 ± 13.7</td>
<td>0.835</td>
</tr>
<tr>
<td>Gender, female</td>
<td>48 (89)</td>
<td>44 (82)</td>
<td>0.417</td>
</tr>
<tr>
<td>Ethnicity</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Chinese</td>
<td>39 (72)</td>
<td>45 (83)</td>
<td/>
</tr>
<tr>
<td> Malay</td>
<td>9 (17)</td>
<td>2 (4)</td>
<td>0.077</td>
</tr>
<tr>
<td> Indian</td>
<td>4 (7)</td>
<td>2 (4)</td>
<td/>
</tr>
<tr>
<td> Others<sup>a</sup></td>
<td>2 (4)</td>
<td>5 (9)</td>
<td/>
</tr>
<tr>
<td>Education, years</td>
<td>13.30 ± 3.6</td>
<td>14.54 ± 3.0</td>
<td>0.053</td>
</tr>
<tr>
<td>Smoker, current</td>
<td>12 (22)</td>
<td>7 (13)</td>
<td>0.312</td>
</tr>
<tr>
<td>Married</td>
<td>28 (52)</td>
<td>31 (57)</td>
<td>0.699</td>
</tr>
<tr>
<td> Serology</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> C3, mg/dl</td>
<td>81.81 ± 27.3</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> C4, mg/dl</td>
<td>16.91 ± 9.1</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> Anti-dsDNA, IU</td>
<td>89.00 ± 78.8</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>SLEDAI</td>
<td>3.85 ± 3.8</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>SLICC/ACR DI</td>
<td>0.39 ± 0.8</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Daily prednisolone dose, mg</td>
<td>10.47 ± 12.1</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Other immunosuppressants<sup><xref ref-type="table-fn" rid="table-fn2-0961203312471872">b</xref></sup></td>
<td/>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> Hydroxychloroquine</td>
<td>42 (78)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> Azathioprine</td>
<td>17 (32)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> Mycophenolate mofetil</td>
<td>7 (13)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> Methotrexate</td>
<td>4 (7)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> Leflunomide</td>
<td>1 (2)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> Cyclosporin</td>
<td>2 (4)</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312471872"><p>SLE: systemic lupus erythematosus; SD: standard deviation; NA: not applicable; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLICC/ACR DI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for SLE <sup>a</sup>One was Burmese and one was Filipino in the SLE group while five were Filipinos in the control group.</p></fn>
<fn id="table-fn2-0961203312471872"><label>b</label><p>Immunosuppressive therapies apart from glucocorticoids. The sum is &gt;100% because one patient may take &gt;1 drugs concurrently.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0961203312471872" position="float"><label>Table 2</label><caption><p>Anxiety and depressive symptoms, health-related quality of life and serum proinflammatory cytokine levels of patients with SLE and healthy controls</p></caption>
<graphic alternate-form-of="table2-0961203312471872" xlink:href="10.1177_0961203312471872-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>SLE (N = 54)<hr/></th>
<th>Healthy controls (N = 54)</th>
<th>p-value</th>
</tr>
<tr><th/>
<th colspan="3">Mean ± SD (range); number (%)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>HADS-Anxiety</td>
<td>5.65 ± 4.1</td>
<td>3.74 ± 2.9</td>
<td>0.022</td>
</tr>
<tr>
<td>HADS-Depression</td>
<td>3.87 ± 3.0</td>
<td>2.33 ± 2.2</td>
<td>0.006</td>
</tr>
<tr>
<td>Anxiety<sup><xref ref-type="table-fn" rid="table-fn4-0961203312471872">a</xref></sup></td>
<td>19 (35)</td>
<td>6 (11)</td>
<td>0.005</td>
</tr>
<tr>
<td>Depression<sup><xref ref-type="table-fn" rid="table-fn4-0961203312471872">a</xref></sup></td>
<td>8 (15)</td>
<td>4 (7)</td>
<td>0.359</td>
</tr>
<tr>
<td>SF-36</td>
<td>67.87 ± 19.8</td>
<td>84.53 ± 8.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td> MH component</td>
<td>64.46 ± 20.0</td>
<td>80.15 ± 11.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td> PH component</td>
<td>66.98 ± 19.1</td>
<td>82.37 ± 9.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Serum cytokine level, pg/ml</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> IL-1β</td>
<td>0.976 ± 5.89 (0–43)</td>
<td>0.275 ± 1.65 (0–12.01)</td>
<td>0.469</td>
</tr>
<tr>
<td> IL-6</td>
<td>8.91 ± 22.1 (0–103.58)</td>
<td>6.14 ± 19.7 (0–127.51)</td>
<td>0.423</td>
</tr>
<tr>
<td> IL-17</td>
<td>6.15 ± 17.4 (0–115.15)</td>
<td>9.51 ± 19.3 (0–83.05)</td>
<td>0.082</td>
</tr>
<tr>
<td> IL-23</td>
<td>196.75 ± 817.3 (0–5854.0)</td>
<td>88.97 ± 295.4 (0–2056.75)</td>
<td>0.741</td>
</tr>
<tr>
<td> IL-33</td>
<td>957.41 ± 6653.2 (0–48466)</td>
<td>34.24 ± 79.3 (0–363.55)</td>
<td>0.356</td>
</tr>
<tr>
<td> TNFα</td>
<td>17.23 ± 13.9 (4.84–67.32)</td>
<td>8.63 ± 5.4 (1.49–26.18)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203312471872"><p>SLE: systemic lupus erythematosus; SD: standard deviation; HADS: Hospital Anxiety and Depression Scale; SF-36: Short Form-36; MH: mental health; PH: physical health; IL: interleukin; TNFα: tumour necrosis factor-alpha.</p></fn>
<fn id="table-fn4-0961203312471872"><label>a</label><p>Using a cut-off score of 8 of the HADS to define anxiety and depression.</p></fn></table-wrap-foot>
</table-wrap></p>
  <p>For serum proinflammatory cytokine levels, SLE patients had a significantly higher level of TNFα than that of the healthy controls (17.23 ± 13.9 <italic>vs</italic>. 8.63 ± 5.4 pg/ml, <italic>p</italic> &lt; 0.001) while there was no difference between the two groups in IL-1ß, IL-6, IL-17, IL-23 and IL-33 levels (see <xref ref-type="table" rid="table2-0961203312471872">Table 2</xref> and <xref ref-type="fig" rid="fig1-0961203312471872">Figure 1(a)</xref> to (<xref ref-type="fig" rid="fig1-0961203312471872">f</xref>)). In univariate analysis, HADS-Anxiety, HADS-Depression, higher serum TNFα level and lower IL-17 level were associated with lower SF-36 score. On multivariate analysis with adjustments for confounders including SLEDAI and SLICC/ACR DI in two separate models, higher serum TNFα (ß = −0.224, <italic>p</italic> = 0.047) remained independently associated with lower SF-36, along with smoking status (ß = −0.253, <italic>p</italic> = 0.014) and more severe depressive symptoms (ß = −0.433, <italic>p</italic> = 0.002) (see <xref ref-type="table" rid="table3-0961203312471872">Table 3</xref>). In healthy controls, serum TNFα level correlated with HADS-Depression on univariate analysis (univariate ß = 0.401, <italic>p</italic> = 0.003). No significant relationship was found between other proinflammatory cytokines, HADS and HRQoL amongst the healthy subjects (data not shown). As reflected by the VIF and P-P and scatter plots of standardized individuals, the regression models were stable and valid (see Supplementary Figures 1 and 2 online).
<table-wrap id="table3-0961203312471872" position="float"><label>Table 3</label><caption><p>Independent predictors for SF-36 in patients with SLE</p></caption>
<graphic alternate-form-of="table3-0961203312471872" xlink:href="10.1177_0961203312471872-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2"/><th colspan="3">Univariate<hr/></th>
<th colspan="6">Multivariate<hr/></th>
</tr>
<tr><th>β</th>
<th>SE</th>
<th><italic>p</italic>-value</th>
<th>β</th>
<th>SE</th>
<th><italic>p</italic>-value</th>
<th>T</th>
<th>VIF</th>
<th><italic>R</italic><sup>2</sup></th>
</tr></thead>
<tbody align="left">
<tr>
<td>Age</td>
<td>0.059</td>
<td>0.001</td>
<td>0.669</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>Women</td>
<td>−0.131</td>
<td>0.063</td>
<td>0.345</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>Married<sup><xref ref-type="table-fn" rid="table-fn6-0961203312471872">a</xref></sup></td>
<td>0.062</td>
<td>0.040</td>
<td>0.658</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>Education, years</td>
<td>−0.040</td>
<td>0.132</td>
<td>0.773</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>Chinese<sup><xref ref-type="table-fn" rid="table-fn7-0961203312471872">b</xref></sup></td>
<td>−0.093</td>
<td>0.044</td>
<td>0.502</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>Malay<sup><xref ref-type="table-fn" rid="table-fn7-0961203312471872">b</xref></sup></td>
<td>0.082</td>
<td>0.053</td>
<td>0.553</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>Indian<sup><xref ref-type="table-fn" rid="table-fn7-0961203312471872">b</xref></sup></td>
<td>−0.056</td>
<td>0.076</td>
<td>0.685</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>Smoking</td>
<td>−0.252</td>
<td>0.062</td>
<td>0.065</td>
<td>−0.253</td>
<td>0.046</td>
<td>0.014</td>
<td>0.930</td>
<td>1.075</td>
<td/>
</tr>
<tr>
<td>HADS-Anxiety</td>
<td>−0.556</td>
<td>0.050</td>
<td>&lt;0.001</td>
<td>−0.213</td>
<td>0.060</td>
<td>0.130</td>
<td>0.481</td>
<td>2.081</td>
<td/>
</tr>
<tr>
<td>HADS-Depression</td>
<td>−0.605</td>
<td>0.051</td>
<td>&lt;0.001</td>
<td>−0.433</td>
<td>0.062</td>
<td>0.002</td>
<td>0.501</td>
<td>1.997</td>
<td/>
</tr>
<tr>
<td>SLEDAI</td>
<td>−0.154</td>
<td>0.054</td>
<td>0.266</td>
<td>−0.008</td>
<td>0.041</td>
<td>0.940</td>
<td>0.827</td>
<td>1.209</td>
<td>0.568</td>
</tr>
<tr>
<td>SLICC/ACR DI</td>
<td>−0.124</td>
<td>0.111</td>
<td>0.271</td>
<td><sup><xref ref-type="table-fn" rid="table-fn8-0961203312471872">c</xref></sup></td>
<td><sup><xref ref-type="table-fn" rid="table-fn8-0961203312471872">c</xref></sup></td>
<td><sup><xref ref-type="table-fn" rid="table-fn8-0961203312471872">c</xref></sup></td>
<td><sup><xref ref-type="table-fn" rid="table-fn8-0961203312471872">c</xref></sup></td>
<td><sup><xref ref-type="table-fn" rid="table-fn8-0961203312471872">c</xref></sup></td>
<td/>
</tr>
<tr>
<td>Prednisolone, mg/day</td>
<td>0.042</td>
<td>0.042</td>
<td>0.268</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>TNFα</td>
<td>−0.350</td>
<td>0.068</td>
<td>&lt;0.001</td>
<td>−0.224</td>
<td>0.058</td>
<td>0.047</td>
<td>0.763</td>
<td>1.310</td>
<td/>
</tr>
<tr>
<td>IL-1</td>
<td>0.084</td>
<td>0.077</td>
<td>0.548</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>IL-6</td>
<td>−0.029</td>
<td>0.032</td>
<td>0.837</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>IL-17</td>
<td>−0.340</td>
<td>0.042</td>
<td>0.012</td>
<td>−0.130</td>
<td>0.038</td>
<td>0.277</td>
<td>0.656</td>
<td>1.525</td>
<td/>
</tr>
<tr>
<td>IL-23</td>
<td>0.159</td>
<td>0.018</td>
<td>0.251</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>IL-33</td>
<td>0.172</td>
<td>0.020</td>
<td>0.214</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0961203312471872"><p>SLE: systemic lupus erythematosus; SE: standard error; β: correlation coefficient; T: tolerance; VIF: variation inflation factor; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLICC/DI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus; IL: interleukin; TNFα: tumour necrosis factor-alpha.</p></fn>
<fn id="table-fn6-0961203312471872"><label>a</label><p>Married versus single, divorced and widowed.</p></fn>
<fn id="table-fn7-0961203312471872"><label>b</label><p>Other ethnicity, i.e. ‘Others’ in <xref ref-type="table" rid="table1-0961203312471872">Table 1</xref> was assigned as the dummy variable.</p></fn>
<fn id="table-fn8-0961203312471872"><label>c</label><p>When SLICC/ACR DI replaced SLEDAI in the multivariate model, the outcome is unaffected. For TNFα: β = −0.226, <italic>p</italic> = 0.049; for smoking: β = −0.225, <italic>p</italic> = 0.012; for depression: β = −0.441, <italic>p</italic> = 0.004; for SLICC/ACR DI: β = 0.011, <italic>p</italic> = 0.925. Other variables remained insignificant, with <italic>R</italic><sup>2 </sup>= 0.568, tolerance ranges from 0.421 to 0.969.</p></fn></table-wrap-foot>
</table-wrap>
<fig id="fig1-0961203312471872" position="float"><label>Figure 1</label><caption><p>Comparisons of serum proinflammatory cytokine levels between patients with SLE and healthy controls. (a) IL-1β, (b) IL-6, (c) IL-17, (d) IL-23, (e) IL-33, (f) TNFα.</p>
<p>IL: interleukin; SLE: systemic lupus erythematosus.</p></caption><graphic xlink:href="10.1177_0961203312471872-fig1.tif"/>
</fig></p>
</sec>
<sec id="sec8-0961203312471872" sec-type="discussion"><title>Discussion</title>
<p>In keeping with most of the published studies, serum TNFα level was found to be significantly higher in patients with SLE than in that of their healthy counterparts.<sup><xref ref-type="bibr" rid="bibr20-0961203312471872">20</xref>,<xref ref-type="bibr" rid="bibr21-0961203312471872">21</xref>,<xref ref-type="bibr" rid="bibr23-0961203312471872">23</xref>,<xref ref-type="bibr" rid="bibr24-0961203312471872">24</xref></sup> Furthermore, two very recent studies demonstrated that higher serum TNFα level was associated with higher SLEDAI score and IFNα level.<sup><xref ref-type="bibr" rid="bibr25-0961203312471872">25</xref>,<xref ref-type="bibr" rid="bibr26-0961203312471872">26</xref></sup> Since IFNα is a pivotal cytokine produced by the plasmacytoid dendritic cells and is elevated in lupus patients with concomitantly high TNFα,<sup><xref ref-type="bibr" rid="bibr26-0961203312471872">26</xref>,<xref ref-type="bibr" rid="bibr27-0961203312471872">27</xref></sup> it is reasonable to postulate that these proinflammatory cytokines can exert a certain impact on mood and HRQoL in patients with SLE. While alteration of the hypothalamic–pituitary axis and monoamine levels such as serotonin and norepinephrine in the central nervous system (CNS) might play a role,<sup><xref ref-type="bibr" rid="bibr28-0961203312471872">28</xref>–</sup><sup><xref ref-type="bibr" rid="bibr31-0961203312471872">31</xref></sup> the mechanism by which proinflammatory cytokines disturb the psychiatric system in humans is largely elusive. In a prospective study addressing the impact of TNFα on patients with major depressive disorder, it was found that at baseline, serum TNFα was significantly higher in patients with depression than in normal controls. Intriguingly, after treatment with antidepressants, the TNFα level of the patients was significantly reduced and was comparable to that of the normal control subjects.<sup><xref ref-type="bibr" rid="bibr32-0961203312471872">32</xref></sup> The results of this early work laid down the foundation of the putative link between inflammation, inflammatory cytokines and depression.</p>
<p>Dissimilar to patients with SLE, we found that serum TNFα level was correlated only with depressive symptoms and not with HRQoL in healthy subjects. In line with other investigators, both young and elderly patients with depression unanimously demonstrated higher proinflammatory cytokine levels including TNFα in both sera and plasma when compared with their normal counterparts.<sup><xref ref-type="bibr" rid="bibr33-0961203312471872">33</xref>,<xref ref-type="bibr" rid="bibr34-0961203312471872">34</xref></sup> While these studies did not assess HRQoL, it is possible that a certain level of TNFα is required to trigger its negative impact on the quality of life. In patients with inflammatory and infective conditions in which the circulating TNFα level can be quite high, such a level may be able to reach the threshold for affecting the HRQoL. Undoubtedly, further studies on this proposed ‘dose–response mechanism’ are required to confirm our hypothesis.</p>
<p>There are several limitations in our study. First, this is a cross-sectional study and hence it is unable to determine the causal relationship between proinflammatory cytokines and quality of life and depression. Second, since the SDs were wide amongst the serum levels of proinflammatory cytokines except those of TNFα, we were unable to detect significant differences between SLE patients and healthy controls in the serum levels of IL-1, IL-6, IL-17, IL-23 and IL-33 even though their mean values appeared to be quite discrepant between the two groups (see <xref ref-type="table" rid="table2-0961203312471872">Table 2</xref>). Because the intra- and inter-assay CV fell into an acceptable range in all the serum analyses, our relatively small sample size might be the main reason why we failed to demonstrate differences amongst the proinflammatory cytokines except TNFα between the two groups. Nevertheless, to ensure the validity of the laboratory data and its analysis, all immunoassays were done as one batch by the same researcher in order to minimize variation of experimental condition. Third, IFNα was not determined in our subjects. This was because ELISA methods of detection of serum IFNα in human samples are of low sensitivity and specificity and our limited funding did not support the more sensitive and reproducible functional reporter cell assay for serum IFNα.<sup><xref ref-type="bibr" rid="bibr26-0961203312471872">26</xref></sup> The mechanisms by which proinflammatory cytokines in our SLE patients led to depressive symptoms and poor HRQoL would have been more revealing if we were able to show concomitant correlations between IFNα and TNFα levels and SF-36 as well as HADS.</p>
<p>In conclusion, serum TNFα is elevated in patients with SLE. Importantly, we hitherto reported that serum TNFα level is independently associated with poorer HRQoL and more severe depressive symptoms in patients in SLE. While the mechanism by which TNFα can result in poor HRQoL and depressive symptoms in patients with SLE remains to be investigated, our observations send out three important messages. First, clinicians taking care of patients with SLE are reminded of potential poor quality of life in their patients especially in those with high TNFα levels, even if the disease activity and damage may not be clinically alarming. This particular subset of patients should be referred for thorough psychosocial evaluation. Second, similar to RA and ankylosing spondylitis (AS), TNFα may lead to poor psychosocial health regardless of organ involvement, disease damage and drug use in patients with SLE. Third, while not frequently assessed in many major clinical trials evaluating therapeutic agents for SLE, psychosocial variables such as HRQoL, depression and anxiety are important secondary outcome measures which are required to be gauged in future trials testing the use of TNFα inhibitors in patients with SLE.</p>
</sec>
</body>
<back><ack>
<title>Acknowledgement</title>
<p>The authors would like to thank Mr Liu Yang, a former postgraduate student in their study team, who collected the clinical and demographic data from the study participants and performed the cytokine analysis.</p>
</ack>
<sec id="sec13-0961203312471872">
<title>Funding</title>
<p>This research was supported by the Yong Loo Lin School of Medicine, National University of Singapore. The grant number is R-172-001-161-133.</p>
</sec>
<sec>
<title>Conflict of interest statement</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312471872"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almehed</surname><given-names>K</given-names></name><name><surname>Carlsten</surname><given-names>H</given-names></name><name><surname>Forsblad-d'Elia</surname><given-names>H</given-names></name></person-group>. <article-title>Health-related quality of life in systemic lupus erythematosus and its association with disease and work disability</article-title>. <source>Scand J Rheumatol</source> <year>2010</year>; <volume>39</volume>: <fpage>58</fpage>–<lpage>62</lpage>.</citation></ref>
<ref id="bibr2-0961203312471872"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>CS</given-names></name><name><surname>Mak</surname><given-names>A</given-names></name></person-group>. <article-title>The socioeconomic burden of SLE</article-title>. <source>Nat Rev Rheumatol</source> <year>2009</year>; <volume>5</volume>: <fpage>400</fpage>–<lpage>404</lpage>.</citation></ref>
<ref id="bibr3-0961203312471872"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jolly</surname><given-names>M</given-names></name></person-group>. <article-title>How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?</article-title> <source>J Rheumatol</source> <year>2005</year>; <volume>32</volume>: <fpage>1706</fpage>–<lpage>1708</lpage>.</citation></ref>
<ref id="bibr4-0961203312471872"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panopalis</surname><given-names>P</given-names></name><name><surname>Clarke</surname><given-names>AE</given-names></name></person-group>. <article-title>Quality of life in systemic lupus erythematosus</article-title>. <source>Clin Dev Immunol</source> <year>2006</year>; <volume>13</volume>: <fpage>321</fpage>–<lpage>324</lpage>.</citation></ref>
<ref id="bibr5-0961203312471872"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McElhone</surname><given-names>K</given-names></name><name><surname>Abbott</surname><given-names>J</given-names></name><name><surname>Teh</surname><given-names>LS</given-names></name></person-group>. <article-title>A review of health related quality of life in systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2006</year>; <volume>15</volume>: <fpage>633</fpage>–<lpage>643</lpage>.</citation></ref>
<ref id="bibr6-0961203312471872"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mak</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>CS</given-names></name><name><surname>Chan</surname><given-names>MF</given-names></name><name><surname>Cheak</surname><given-names>AA</given-names></name><name><surname>Ho</surname><given-names>RC</given-names></name></person-group>. <article-title>Damage accrual, cumulative glucocorticoid dose and depression predict anxiety in patients with systemic lupus erythematosus</article-title>. <source>Clin Rheumatol</source> <year>2011</year>; <volume>30</volume>: <fpage>795</fpage>–<lpage>803</lpage>.</citation></ref>
<ref id="bibr7-0961203312471872"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stoll</surname><given-names>T</given-names></name><name><surname>Gordon</surname><given-names>C</given-names></name><name><surname>Seifert</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>1997</year>; <volume>24</volume>: <fpage>1608</fpage>–<lpage>1614</lpage>.</citation></ref>
<ref id="bibr8-0961203312471872"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strand</surname><given-names>V</given-names></name><name><surname>Aranow</surname><given-names>C</given-names></name><name><surname>Cardiel</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo</article-title>. <source>Lupus</source> <year>2003</year>; <volume>12</volume>: <fpage>677</fpage>–<lpage>686</lpage>.</citation></ref>
<ref id="bibr9-0961203312471872"><label>9</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Ranjith</surname><given-names>G</given-names></name><name><surname>Pariante</surname><given-names>C</given-names></name></person-group>. <article-title>Psychiatric toxicity of interferon-α: A model for understanding the etiology of major depression and chronic fatigue syndrome?</article-title> In: <person-group person-group-type="editor"><name><surname>Plotnikoff</surname><given-names>NP</given-names></name><name><surname>Faith</surname><given-names>RE</given-names></name><name><surname>Murgo</surname><given-names>AJ</given-names></name><name><surname>Good</surname><given-names>RA</given-names></name></person-group> (eds). <source><italic>Cytokine stress and immunity</italic></source> <edition>2nd edn</edition> <publisher-loc>Florida</publisher-loc>: <publisher-name>CRC Press</publisher-name>, <year>2007</year> <fpage>349</fpage>–<lpage>358</lpage>.</citation></ref>
<ref id="bibr10-0961203312471872"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonaccorso</surname><given-names>S</given-names></name><name><surname>Puzella</surname><given-names>A</given-names></name><name><surname>Marino</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms</article-title>. <source>Psychiatry Res</source> <year>2001</year>; <volume>105</volume>: <fpage>45</fpage>–<lpage>55</lpage>.</citation></ref>
<ref id="bibr11-0961203312471872"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loftis</surname><given-names>JM</given-names></name><name><surname>Hauser</surname><given-names>P</given-names></name></person-group>. <article-title>The phenomenology and treatment of interferon-induced depression</article-title>. <source>J Affect Disord</source> <year>2004</year>; <volume>82</volume>: <fpage>175</fpage>–<lpage>190</lpage>.</citation></ref>
<ref id="bibr12-0961203312471872"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr13-0961203312471872"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Härter</surname><given-names>M</given-names></name><name><surname>Woll</surname><given-names>S</given-names></name><name><surname>Wunsch</surname><given-names>A</given-names></name><name><surname>Bengel</surname><given-names>J</given-names></name><name><surname>Reuter</surname><given-names>K</given-names></name></person-group>. <article-title>Screening for mental disorders in cancer, cardiovascular and musculoskeletal diseases. Comparison of HADS and GHQ-12</article-title>. <source>Soc Psychiatry Psychiatr Epidemiol</source> <year>2006</year>; <volume>41</volume>: <fpage>56</fpage>–<lpage>62</lpage>.</citation></ref>
<ref id="bibr14-0961203312471872"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thumboo</surname><given-names>J</given-names></name><name><surname>Fong</surname><given-names>KY</given-names></name><name><surname>Chan</surname><given-names>SP</given-names></name><etal/></person-group>. <article-title>A prospective study of factors affecting quality of life in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2000</year>; <volume>27</volume>: <fpage>1414</fpage>–<lpage>1420</lpage>.</citation></ref>
<ref id="bibr15-0961203312471872"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Goldsmith</surname><given-names>CH</given-names></name><etal/></person-group>. <article-title>The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>809</fpage>–<lpage>813</lpage>.</citation></ref>
<ref id="bibr16-0961203312471872"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Goldsmith</surname><given-names>CH</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><etal/></person-group>. <article-title>Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: International validation</article-title>. <source>J Rheumatol</source> <year>1994</year>; <volume>21</volume>: <fpage>1468</fpage>–<lpage>1471</lpage>.</citation></ref>
<ref id="bibr17-0961203312471872"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>MY</given-names></name><name><surname>Wu</surname><given-names>HJ</given-names></name><name><surname>Lo</surname><given-names>Y</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name></person-group>. <article-title>The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2010</year>; <volume>37</volume>: <fpage>2046</fpage>–<lpage>2052</lpage>.</citation></ref>
<ref id="bibr18-0961203312471872"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>HY</given-names></name><name><surname>Chung</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>HA</given-names></name><etal/></person-group>. <article-title>Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus</article-title>. <source>J Clin Immunol</source> <year>2007</year>; <volume>27</volume>: <fpage>461</fpage>–<lpage>466</lpage>.</citation></ref>
<ref id="bibr19-0961203312471872"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>MY</given-names></name><name><surname>Huang</surname><given-names>FP</given-names></name><name><surname>Ip</surname><given-names>WK</given-names></name><etal/></person-group>. <article-title>Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus</article-title>. <source>Rheumatology (Oxford)</source> <year>2010</year>; <volume>49</volume>: <fpage>520</fpage>–<lpage>527</lpage>.</citation></ref>
<ref id="bibr20-0961203312471872"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabay</surname><given-names>C</given-names></name><name><surname>Cakir</surname><given-names>N</given-names></name><name><surname>Moral</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity</article-title>. <source>J Rheumatol</source> <year>1997</year>; <volume>24</volume>: <fpage>303</fpage>–<lpage>308</lpage>.</citation></ref>
<ref id="bibr21-0961203312471872"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Studnicka-Benke</surname><given-names>A</given-names></name><name><surname>Steiner</surname><given-names>G</given-names></name><name><surname>Petera</surname><given-names>P</given-names></name><name><surname>Smolen</surname><given-names>JS</given-names></name></person-group>. <article-title>Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus</article-title>. <source>Br J Rheumatol</source> <year>1996</year>; <volume>35</volume>: <fpage>1067</fpage>–<lpage>1074</lpage>.</citation></ref>
<ref id="bibr22-0961203312471872"><label>22</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Field</surname><given-names>A</given-names></name></person-group>. <source>Discovering statistics using SPSS. Regression</source> <edition>3rd edn</edition>, <publisher-loc>London</publisher-loc>: <publisher-name>Sage</publisher-name>, <year>2005</year> <fpage>197</fpage>–<lpage>263</lpage>.</citation></ref>
<ref id="bibr23-0961203312471872"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabry</surname><given-names>A</given-names></name><name><surname>Elbasyouni</surname><given-names>SR</given-names></name><name><surname>Sheashaa</surname><given-names>HA</given-names></name><etal/></person-group>. <article-title>Correlation between levels of TNF-alpha and IL-6 and hematological involvement in SLE Egyptian patients with lupus nephritis</article-title>. <source>Int Urol Nephrol</source> <year>2006</year>; <volume>38</volume>: <fpage>731</fpage>–<lpage>737</lpage>.</citation></ref>
<ref id="bibr24-0961203312471872"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Studnicka-Benke</surname><given-names>A</given-names></name><name><surname>Steiner</surname><given-names>G</given-names></name><name><surname>Petera</surname><given-names>P</given-names></name><name><surname>Smolen</surname><given-names>JS</given-names></name></person-group>. <article-title>Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus</article-title>. <source>Br J Rheumatol</source> <year>1996</year>; <volume>35</volume>: <fpage>1067</fpage>–<lpage>1074</lpage>.</citation></ref>
<ref id="bibr25-0961203312471872"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>V</given-names></name><name><surname>Verma</surname><given-names>J</given-names></name><name><surname>Marwah</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Anand</surname><given-names>D</given-names></name><name><surname>Das</surname><given-names>N</given-names></name></person-group>. <article-title>Cytokine imbalance in systemic lupus erythematosus: A study on northern Indian subjects</article-title>. <source>Lupus</source> <year>2012</year>; <volume>21</volume>: <fpage>596</fpage>–<lpage>603</lpage>.</citation></ref>
<ref id="bibr26-0961203312471872"><label>26</label><citation citation-type="other"><comment>Weckerle CE, Imbuka D, Franek BS, et al. Large scale analysis of tumor necrosis factor alpha levels in systemic lupus erythematosus. <italic>Arthritis Rheum</italic>. Epub ahead of print 5 April 2012. DOI: 10.1002/art.34483</comment>.</citation></ref>
<ref id="bibr27-0961203312471872"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weckerle</surname><given-names>CE</given-names></name><name><surname>Franek</surname><given-names>BS</given-names></name><name><surname>Kelly</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2011</year>; <volume>63</volume>: <fpage>1044</fpage>–<lpage>1053</lpage>.</citation></ref>
<ref id="bibr28-0961203312471872"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Connor</surname><given-names>TJ</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Leonard</surname><given-names>BE</given-names></name><name><surname>Merali</surname><given-names>Z</given-names></name><name><surname>Anisman</surname><given-names>H</given-names></name></person-group>. <article-title>An assessment of the effects of central interleukin-1beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat</article-title>. <source>Neuroscience</source> <year>1998</year>; <volume>84</volume>: <fpage>923</fpage>–<lpage>933</lpage>.</citation></ref>
<ref id="bibr29-0961203312471872"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>BJ</given-names></name></person-group>. <article-title>The dexamethasone suppression test for melancholia</article-title>. <source>Br J Psychiatry</source> <year>1982</year>; <volume>140</volume>: <fpage>292</fpage>–<lpage>304</lpage>.</citation></ref>
<ref id="bibr30-0961203312471872"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Myint</surname><given-names>AM</given-names></name><name><surname>Kim</surname><given-names>YK</given-names></name></person-group>. <article-title>Cytokine-serotonin interaction through IDO: A neurodegeneration hypothesis of depression</article-title>. <source>Med Hypotheses</source> <year>2003</year>; <volume>61</volume>: <fpage>519</fpage>–<lpage>525</lpage>.</citation></ref>
<ref id="bibr31-0961203312471872"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zalcman</surname><given-names>S</given-names></name><name><surname>Green-Johnson</surname><given-names>JM</given-names></name><name><surname>Murray</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6</article-title>. <source>Brain Res</source> <year>1994</year>; <volume>643</volume>: <fpage>40</fpage>–<lpage>49</lpage>.</citation></ref>
<ref id="bibr32-0961203312471872"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tuglu</surname><given-names>C</given-names></name><name><surname>Kara</surname><given-names>SH</given-names></name><name><surname>Caliyurt</surname><given-names>O</given-names></name><name><surname>Vardar</surname><given-names>E</given-names></name><name><surname>Abay</surname><given-names>E</given-names></name></person-group>. <article-title>Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder</article-title>. <source>Psychopharmacology (Berl)</source> <year>2003</year>; <volume>170</volume>: <fpage>429</fpage>–<lpage>433</lpage>.</citation></ref>
<ref id="bibr33-0961203312471872"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>AJ</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>Morris</surname><given-names>C</given-names></name><name><surname>Jackson</surname><given-names>E</given-names></name><name><surname>Harrison</surname><given-names>R</given-names></name><name><surname>O'Brien</surname><given-names>JT</given-names></name></person-group>. <article-title>Increase in interleukin-1beta in late-life depression</article-title>. <source>Am J Psychiatry</source> <year>2005</year>; <volume>162</volume>: <fpage>175</fpage>–<lpage>177</lpage>.</citation></ref>
<ref id="bibr34-0961203312471872"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trzonkowski</surname><given-names>P</given-names></name><name><surname>Myśliwska</surname><given-names>J</given-names></name><name><surname>Godlewska</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Immune consequences of the spontaneous proinflammatory status in depressed elderly patients</article-title>. <source>Brain Behav Immun</source> <year>2004</year>; <volume>18</volume>: <fpage>135</fpage>–<lpage>148</lpage>.</citation></ref>
</ref-list>
</back>
</article>